11-Aug-2026
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
TipRanks (Tue, 11-Aug 7:16 AM ET)
Trump executive order makes major changes to childhood vaccines schedule
Seeking Alpha News (Mon, 10-Aug 2:59 PM ET)
Trump executive order set to make major changes to childhood vaccines schedule
Seeking Alpha News (Mon, 10-Aug 2:59 PM ET)
Market Chameleon (Tue, 28-Jul 7:47 AM ET)
New survey reveals Canadians underestimate chronic hepatitis B and its link to liver cancer
PRNewswire (Tue, 28-Jul 7:00 AM ET)
Market Chameleon (Thu, 23-Jul 5:06 AM ET)
PRNewswire (Wed, 22-Jul 1:59 PM ET)
Business Wire (Mon, 13-Jul 1:30 PM ET)
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Globe Newswire (Wed, 24-Jun 8:30 AM ET)
Globe Newswire (Wed, 17-Jun 12:36 PM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of August 11, 2026, GSK stock price declined to $50.90 with 2,680,395 million shares trading.
GSK has a beta of 0.34, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.02 to the broad based SPY ETF.
GSK has a market cap of $102.02 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $11 billion in Revenue and $1.35 earnings per share. This beat revenue expectation by $490 million and exceeded earnings estimates by $.08.
In the last 3 years, GSK traded as high as $61.70 and as low as $31.72.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): AVDE, FENI, PPH, FVD, GMOI.
GSK has outperformed the market in the last year with a return of +39.4%, while the SPY ETF gained +22.1%. However, in the most recent history, GSK shares have underperformed the stock market with its stock returning +1.9% in the last 3 month period and -2.1% for the last 2 week period, while SPY has returned +4.7% and +4.3%, respectively.
GSK support price is $51.25 and resistance is $53.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK shares will trade within this expected range on the day.